A Phase 3 interventional study of Mirikizumab and Mirikizumab in Ulcerative Colitis and Ulcerative Colitis Chronic, sponsored by Eli Lilly and Company. Completed at 120 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 7th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 8th registered.
1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18–75
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
Specialty Networks Research. · Sites in United States
Ages 21+
Rubix LS · Sites in United States
Ages 60–99
By country, each count listing its studies:
mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2023.
This study's enrollment of 172 is above the median of 70 across 1,238 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 172 across the 13 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 5 most frequent:
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
16 studies in Colitis, Ulcerative by Eli Lilly and Company: 5 open now, 7 under way, 3 of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, this one is the 9th largest by enrollment, is one of 2 that started in 2023, is one of 8 in phase 3, and was the 10th registered.
Eli Lilly and Company’s Colitis, Ulcerative studies by the year they started, since 2015.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 16 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 300 milligram (mg) mirikizumab every 4 weeks (Q4W) at week 0, 4, and 8 administered intravenously (IV).
Drug: Mirikizumab
Administered IV
Also known as: LY3074828
Administered Subcutaneously (SC)
Also known as: LY3074828
Change From Baseline in Bowel Urgency Severity Urgency Numeric Rating Scale (UNRS)
The UNRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency). Higher scores indicate more severe urgency. Baseline Observation Carried Forward (BOCF) endpoint was defined as the baseline value for participants discontinued during acute phase and defined as the last non-missing observation in the treatment phase for all other randomized participants.
Time frame: Baseline, Week 12
Change From Baseline in Bowel Urgency Frequency (BUF)
BUF is participant reported single item measure of the number of urgent bowel movements reported in the past 24 hours.
Time frame: Baseline, Week 12
Percentage of Participants Achieving Clinically Meaningful Improvement in BUF
This outcome measures the percentage of participants who experience a clinically meaningful reduction in the frequency of bowel urgency episodes from baseline to the 12 week treatment period. Results for this outcome will be reported during final results posting.
Time frame: Baseline to Week 12
Percentage of Participants With Stool Deferral Time (SDT) Intervals at Week 12
The SDT is a participant-reported single item measure of the average duration a patient could delay defecation in the past 24 hours. The shortest weekly SDT is used for analysis of SDT in minutes by taking the shortest response (i.e. minimum value) available over the past 7 days, where no urgency is treated as the largest value. The SDT categories were:\<1 min, ≥1 min to \<2 min, ≥2 min to \<5 min, ≥5 min to \<15 min, and ≥15 min or no urgency. No urgency indicates participant's selected "Did not feel urge to have a bowel movement in the past 24 hours" for all available days in 7-day period.
Time frame: Week 12
Percentage of Participants Achieving Clinically Meaningful Improvement of SDT
This outcome measures the percentage of participants who demonstrate a clinically meaningful improvement in SDT. Results for this outcome will be reported during final results posting.
Time frame: Week 12
Percentage of Participants Achieving Both Clinical Remission, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score of ≤1
Clinical remission based on MMS is defined as Stool Frequency (SF) sub score (range 0-3, higher is worse) = 0, or SF = 1 with a ≥1- point decrease from baseline, and 1. Rectal Bleeding (RB) sub score (range 0-3, higher is worse) = 0, and 2. Endoscopic sub score (ES) (range 0-3, higher is worse) = 0 or 1 (excluding friability). UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency) This outcome assesses the proportion of participants who achieved both a clinical response, as defined by an MMS, and an improvement of ≥3 points from baseline in a UNRS score at Week 12.
Time frame: Week 12
Percentage of Participants Achieving Both Clinical Response, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score ≥3 Points of Improvement From Baseline
Clinical response based on MMS is defined as: 1. A change in the MMS of ≤ -2 points and ≤ -30% change from baseline, and 2. A change of ≤-1 point in the RB subscore (range 0-3, higher is worse) from baseline or a RB score of 0 or 1. UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency) This outcome measures the percentage of participants achieving both, clinical response, based on the MMS, and a UNRS score of ≥3 points of improvement from baseline at 12 weeks.
Time frame: Week 12
Pairwise Correlations Between the Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures
UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency). BUF measures the number of urgent bowel movements reported in the past 24 hours. SDT measures the average duration a patient could delay defecation in the past 24 hours. APU is a single item to assess participant's need to wear an adult diaper, pad or protection because of bowel urgency. This outcome evaluates the pairwise correlations among four bowel urgency-related measures above.
Time frame: Baseline to Week 12
Pairwise Correlations Between Change From Baseline in Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures
UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency). BUF measures the number of urgent bowel movements reported in the past 24 hours. SDT measures the average duration a patient could delay defecation in the past 24 hours. APU is a single item to assess participant's need to wear an adult diaper, pad or protection because of bowel urgency. This outcome evaluates the pairwise correlations between the change in correlations among four bowel urgency-related measures above.
Time frame: Baseline, Week 12
Correlation Between Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF),Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures,With Quality of Life (QoL)/Functional Outcome Measures and UC Symptom Measures
This outcome evaluates correlations between UNRS, BUF, SDT, APU, and patient-reported outcomes (PROs) related to quality of life (QoL), functional outcomes, and UC symptoms. QoL is assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), a 32-item patient-completed tool with four domains: bowel (score range 10-70), systemic (5-35), emotional (12-84), and social (5-35). Each item is rated on a 7-point Likert scale (1 = very severe problem,7 = not a problem at all); The total IBDQ score is calculated by summing the scores from all four domains and total score range is 32-224 (Higher = better QoL). Functional outcomes measures: Work Productivity and Activity Impairment (WPAI) questionnaire (four scores derived: absenteeism, presenteeism, productivity loss, activity impairment; each score 0-100%, higher = greater impairment) and Generalized Anxiety Disorder-7 (GAD-7; total score range 0-21, higher = more severe anxiety)... (Continued below due to character constraint)
Time frame: Baseline to Week 12 UC symptom measures:Patient Global Rating of Severity (PGR-S)(1-6),Patient Global Impression of Change (PGI-C)(1-7),Mayo SF/RB (0-3),Abdominal pain/fatigue NRS (0-10),nocturnal stool frequency;higher=worse severity for all measures.
Correlation Between Change From Baseline in Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures, With QoL/Functional Outcome Measures and UC Symptom Measures
This outcome evaluates correlations between change from baseline in UNRS, BUF, SDT, APU, and PROs related to quality of life (QoL), functional outcomes, and UC symptoms. QoL is assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), a 32-item patient-completed tool with four domains: bowel (score range 10-70), systemic (5-35), emotional (12-84), and social (5-35). Each item is rated on a 7-point Likert scale (1 = very severe problem, 7 = not a problem at all); The total IBDQ score is calculated by summing the scores from all four domains and total score range is 32-224 (Higher = better QoL). Functional outcomes measures: Work Productivity and Activity Impairment (WPAI) questionnaire (four scores derived: absenteeism, presenteeism, productivity loss, activity impairment; each score 0-100%, higher = greater impairment) and Generalized Anxiety Disorder-7 (GAD-7;total score range 0-21, higher = more severe anxiety)... (Continued below due to character constraint)
Time frame: Baseline, Week 12 UC symptom measures:Patient Global Rating of Severity (PGR-S)(1-6),Patient Global Impression of Change (PGI-C)(1-7),Mayo SF/RB (0-3),Abdominal pain/fatigue NRS (0-10),nocturnal stool frequency; higher=worse severity for all measures.
| Milestone | 300 mg Mirikizumab |
|---|---|
| Started | 172 |
| Received at least one dose of study drug | 172 |
| Completed | 155 |
| Not completed | 17 |
| Withdrew: Adverse event | 2 |
| Withdrew: Protocol deviation | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Lack of efficacy | 11 |
| Withdrew: Assigned treatment by mistake | 1 |
The UNRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency). Higher scores indicate more severe urgency. Baseline Observation Carried Forward (BOCF) endpoint was defined as the baseline value for participants discontinued during acute phase and defined as the last non-missing observation in the treatment phase for all other randomized participants.
| score on a scale | 300 mg Mirikizumab |
|---|---|
| Change From Baseline in Bowel Urgency Severity Urgency Numeric Rating Scale (UNRS) | -3.25 (-3.63 to -2.87) |
BUF is participant reported single item measure of the number of urgent bowel movements reported in the past 24 hours.
| counts of urgent bowel movements/day | 300 mg Mirikizumab |
|---|---|
| Change From Baseline in Bowel Urgency Frequency (BUF) | -3.83 (-4.33 to -3.33) |
This outcome measures the percentage of participants who experience a clinically meaningful reduction in the frequency of bowel urgency episodes from baseline to the 12 week treatment period. Results for this outcome will be reported during final results posting.
Results for this outcome have not been posted.
The SDT is a participant-reported single item measure of the average duration a patient could delay defecation in the past 24 hours. The shortest weekly SDT is used for analysis of SDT in minutes by taking the shortest response (i.e. minimum value) available over the past 7 days, where no urgency is treated as the largest value. The SDT categories were:\<1 min, ≥1 min to \<2 min, ≥2 min to \<5 min, ≥5 min to \<15 min, and ≥15 min or no urgency. No urgency indicates participant's selected "Did not feel urge to have a bowel movement in the past 24 hours" for all available days in 7-day period.
| percentage of participants | 300 mg Mirikizumab |
|---|---|
| <1 min | 8.7 |
| >=1 to <2 min | 21.5 |
| >=2 to <5 min | 30.2 |
| >=5 to <15 min | 23.8 |
| >=15 min or no urgency | 15.7 |
This outcome measures the percentage of participants who demonstrate a clinically meaningful improvement in SDT. Results for this outcome will be reported during final results posting.
Results for this outcome have not been posted.
Clinical remission based on MMS is defined as Stool Frequency (SF) sub score (range 0-3, higher is worse) = 0, or SF = 1 with a ≥1- point decrease from baseline, and 1. Rectal Bleeding (RB) sub score (range 0-3, higher is worse) = 0, and 2. Endoscopic sub score (ES) (range 0-3, higher is worse) = 0 or 1 (excluding friability). UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency) This outcome assesses the proportion of participants who achieved both a clinical response, as defined by an MMS, and an improvement of ≥3 points from baseline in a UNRS score at Week 12.
| percentage of participants | 300 mg Mirikizumab |
|---|---|
| Percentage of Participants Achieving Both Clinical Remission, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score of ≤1 | 5.23 |
Clinical response based on MMS is defined as: 1. A change in the MMS of ≤ -2 points and ≤ -30% change from baseline, and 2. A change of ≤-1 point in the RB subscore (range 0-3, higher is worse) from baseline or a RB score of 0 or 1. UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency) This outcome measures the percentage of participants achieving both, clinical response, based on the MMS, and a UNRS score of ≥3 points of improvement from baseline at 12 weeks.
| percentage of participants | 300 mg Mirikizumab |
|---|---|
| Percentage of Participants Achieving Both Clinical Response, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score ≥3 Points of Improvement From Baseline | 44.19 |
UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency). BUF measures the number of urgent bowel movements reported in the past 24 hours. SDT measures the average duration a patient could delay defecation in the past 24 hours. APU is a single item to assess participant's need to wear an adult diaper, pad or protection because of bowel urgency. This outcome evaluates the pairwise correlations among four bowel urgency-related measures above.
| Spearman Correlation Coefficient | 300 mg Mirikizumab |
|---|---|
| Correlation between UNRS and BUF | 0.68 (0.58 to 0.75) |
| Correlation between UNRS and SDT | -0.50 (-0.61 to -0.37) |
| Correlation between UNRS and APU | 0.37 (0.22 to 0.50) |
| Correlation between BUF and SDT | -0.47 (-0.58 to -0.34) |
| Correlation between BUF and APU | 0.45 (0.31 to 0.56) |
| Correlation between SDT and APU | -0.37 (-0.49 to -0.22) |
UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency). BUF measures the number of urgent bowel movements reported in the past 24 hours. SDT measures the average duration a patient could delay defecation in the past 24 hours. APU is a single item to assess participant's need to wear an adult diaper, pad or protection because of bowel urgency. This outcome evaluates the pairwise correlations between the change in correlations among four bowel urgency-related measures above.
| Spearman Correlation Coefficient | 300 mg Mirikizumab |
|---|---|
| Correlation between UNRS and BUF | 0.49 (0.36 to 0.60) |
| Correlation between UNRS and SDT | -0.48 (-0.59 to -0.35) |
| Correlation between UNRS and APU | 0.17 (0.01 to 0.32) |
| Correlation between BUF and SDT | -0.27 (-0.41 to -0.12) |
| Correlation between BUF and APU | 0.16 (0.00 to 0.31) |
| Correlation between SDT and APU | 0.07 (-0.09 to 0.23) |
This outcome evaluates correlations between UNRS, BUF, SDT, APU, and patient-reported outcomes (PROs) related to quality of life (QoL), functional outcomes, and UC symptoms. QoL is assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), a 32-item patient-completed tool with four domains: bowel (score range 10-70), systemic (5-35), emotional (12-84), and social (5-35). Each item is rated on a 7-point Likert scale (1 = very severe problem,7 = not a problem at all); The total IBDQ score is calculated by summing the scores from all four domains and total score range is 32-224 (Higher = better QoL). Functional outcomes measures: Work Productivity and Activity Impairment (WPAI) questionnaire (four scores derived: absenteeism, presenteeism, productivity loss, activity impairment; each score 0-100%, higher = greater impairment) and Generalized Anxiety Disorder-7 (GAD-7; total score range 0-21, higher = more severe anxiety)... (Continued below due to character constraint)
| Spearman Correlation Coefficient | 300 mg Mirikizumab |
|---|---|
| UNRS-IBDQ: IBDQ Total score | -0.55 (-0.65 to -0.42) |
| UNRS-IBDQ: Bowel symptoms | -0.48 (-0.60 to -0.35) |
| UNRS-IBDQ: Systemic symptoms | -0.50 (-0.61 to -0.37) |
| UNRS-IBDQ: Emotional function | -0.51 (-0.62 to -0.38) |
| UNRS-IBDQ: Social function | -0.49 (-0.61 to -0.36) |
| UNRS-WPAI: Work Productivity Loss Score | 0.40 (0.21 to 0.55) |
| UNRS-WPAI: Absenteeism Score | 0.28 (0.10 to 0.45) |
| UNRS-WPAI: Presenteeism Score | 0.39 (0.21 to 0.55) |
| UNRS-WPAI: Activity Impairment Score | 0.54 (0.41 to 0.64) |
| UNRS-Generalize Anxiety Disorder-7 Score | 0.36 (0.21 to 0.49) |
| BUF-IBDQ: IBDQ Total score | -0.60 (-0.69 to -0.48) |
| BUF-IBDQ: Bowel symptoms | -0.57 (-0.67 to -0.45) |
| BUF-IBDQ: Systemic symptoms | -0.57 (-0.67 to -0.45) |
| BUF-IBDQ: Emotional function | -0.51 (-0.62 to -0.37) |
| BUF-IBDQ: Social function | -0.58 (-0.68 to -0.46) |
| BUF-WPAI: Work Productivity Loss Score | 0.50 (0.33 to 0.63) |
| BUF-WPAI: Absenteeism Score | 0.27 (0.08 to 0.43) |
| BUF-WPAI: Presenteeism Score | 0.50 (0.33 to 0.63) |
| BUF-WPAI: Activity Impairment Score | 0.60 (0.48 to 0.69) |
| BUF-Generalize Anxiety Disorder-7 Score | 0.35 (0.20 to 0.48) |
| SDT-IBDQ: IBDQ Total score | 0.37 (0.22 to 0.50) |
| SDT-IBDQ: Bowel symptoms | 0.36 (0.21 to 0.49) |
| SDT-IBDQ: Systemic symptoms | 0.34 (0.19 to 0.48) |
| SDT-IBDQ: Emotional function | 0.32 (0.16 to 0.46) |
| SDT-IBDQ: Social function | 0.34 (0.19 to 0.48) |
| SDT-WPAI: UC Work Productivity Loss Score | -0.29 (-0.46 to -0.10) |
| SDT-WPAI: UC Absenteeism Score | -0.18 (-0.36 to 0.01) |
| SDT-WPAI: UC Presenteeism Score | -0.30 (-0.47 to -0.11) |
| SDT-WPAI: UC Activity Impairment Score | -0.29 (-0.43 to -0.14) |
| SDT-Generalize Anxiety Disorder-7 Score | -0.26 (-0.40 to -0.11) |
| SDT-APU for BU | -0.37 (-0.49 to -0.22) |
| APU-IBDQ: IBDQ Total score | -0.51 (-0.62 to -0.38) |
| APU-IBDQ: Bowel symptoms | -0.46 (-0.58 to -0.32) |
| APU-IBDQ: Systemic symptoms | -0.43 (-0.56 to -0.29) |
| APU-IBDQ: Emotional function | -0.45 (-0.57 to -0.30) |
| APU-IBDQ: Social function | -0.54 (-0.64 to -0.41) |
| APU-WPAI: Work Productivity Loss Score | 0.43 (0.25 to 0.58) |
| APU-WPAI: Absenteeism Score | 0.22 (0.03 to 0.40) |
| APU-WPAI: Presenteeism Score | 0.41 (0.22 to 0.56) |
| APU-WPAI: Activity Impairment Score | 0.48 (0.34 to 0.59) |
| APU-Generalize Anxiety Disorder-7 Score | 0.25 (0.09 to 0.39) |
| UNRS: PGR-S | 0.64 (0.54 to 0.72) |
| UNRS: PGI-C | 0.45 (0.31 to 0.56) |
| UNRS: Mayo SF | 0.35 (0.20 to 0.48) |
| UNRS: Mayo RB | 0.21 (0.05 to 0.35) |
| UNRS: Abdominal Pain NRS | 0.62 (0.51 to 0.70) |
| UNRS: Fatigue NRS | 0.58 (0.47 to 0.67) |
| UNRS: Nocturnal Stool | 0.49 (0.36 to 0.59) |
| BUF: PGR-S | 0.65 (0.56 to 0.73) |
| BUF: PGI-C | 0.45 (0.31 to 0.56) |
| BUF: Mayo SF | 0.53 (0.40 to 0.63) |
| BUF: Mayo RB | 0.22 (0.07 to 0.36) |
| BUF: Abdominal Pain NRS | 0.55 (0.43 to 0.65) |
| BUF: Fatigue NRS | 0.49 (0.36 to 0.60) |
| BUF: Nocturnal Stool | 0.62 (0.51 to 0.70) |
| SDT: PGR-S | -0.44 (-0.56 to -0.31) |
| SDT:Absolute SF | -0.30 (-0.43 to -0.15) |
| SDT: Mayo SF | -0.28 (-0.41 to -0.13) |
| SDT: Mayo RB | -0.22 (-0.36 to -0.07) |
| SDT: Abdominal Pain NRS | -0.44 (-0.55 to -0.30) |
| SDT: Fatigue NRS | -0.30 (-0.43 to -0.15) |
| SDT: Nocturnal Stool | -0.33 (-0.46 to -0.19) |
| SDT: PGI-C | -0.29 (-0.43 to -0.14) |
| APU: PGR-S | 0.39 (0.25 to 0.52) |
| APU: PGI-C | 0.35 (0.20 to 0.48) |
| APU: Mayo SF | 0.44 (0.30 to 0.55) |
| APU: Mayo RB | 0.22 (0.06 to 0.36) |
| APU: Abdominal Pain NRS | 0.23 (0.07 to 0.37) |
| APU: Fatigue NRS | 0.29 (0.14 to 0.43) |
| APU: Nocturnal Stool | 0.50 (0.37 to 0.61) |
This outcome evaluates correlations between change from baseline in UNRS, BUF, SDT, APU, and PROs related to quality of life (QoL), functional outcomes, and UC symptoms. QoL is assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), a 32-item patient-completed tool with four domains: bowel (score range 10-70), systemic (5-35), emotional (12-84), and social (5-35). Each item is rated on a 7-point Likert scale (1 = very severe problem, 7 = not a problem at all); The total IBDQ score is calculated by summing the scores from all four domains and total score range is 32-224 (Higher = better QoL). Functional outcomes measures: Work Productivity and Activity Impairment (WPAI) questionnaire (four scores derived: absenteeism, presenteeism, productivity loss, activity impairment; each score 0-100%, higher = greater impairment) and Generalized Anxiety Disorder-7 (GAD-7;total score range 0-21, higher = more severe anxiety)... (Continued below due to character constraint)
| Spearman Correlation Coefficient | 300 mg Mirikizumab |
|---|---|
| UNRS-IBDQ: IBDQ Total score | -0.546 (-0.654 to -0.414) |
| UNRS-IBDQ: Bowel symptoms | -0.522 (-0.634 to -0.385) |
| UNRS-IBDQ: Systemic symptoms | -0.473 (-0.594 to -0.329) |
| UNRS-IBDQ: Emotional function | -0.485 (-0.604 to -0.342) |
| UNRS-IBDQ: Social function | -0.454 (-0.578 to -0.307) |
| UNRS-WPAI: Work Productivity Loss Score | 0.488 (0.286 to 0.645) |
| UNRS-WPAI: Absenteeism Score | 0.092 (-0.108 to 0.285) |
| UNRS-WPAI: Presenteeism Score | 0.509 (0.312 to 0.661) |
| UNRS-WPAI: Activity Impairment Score | 0.451 (0.309 to 0.571) |
| UNRS-Generalize Anxiety Disorder-7 Score | 0.179 (0.015 to 0.331) |
| BUF-IBDQ: IBDQ Total score | -0.399 (-0.532 to -0.245) |
| BUF-IBDQ: Bowel symptoms | -0.380 (-0.515 to -0.223) |
| BUF-IBDQ: Systemic symptoms | -0.353 (-0.492 to -0.194) |
| BUF-IBDQ: Emotional function | -0.278 (-0.427 to -0.113) |
| BUF-IBDQ: Social function | -0.378 (-0.514 to -0.222) |
| BUF-WPAI: Work Productivity Loss Score | 0.275 (0.044 to 0.475) |
| BUF-WPAI: Absenteeism Score | 0.150 (-0.051 to 0.338) |
| BUF-WPAI: Presenteeism Score | 0.275 (0.045 to 0.475) |
| BUF-WPAI: Activity Impairment Score | 0.356 (0.203 to 0.489) |
| BUF-WPAI: Generalize Anxiety Disorder-7 Score | 0.130 (-0.034 to 0.287) |
| SDT-IBDQ: IBDQ Total score | 0.22 (0.05 to 0.38) |
| SDT-IBDQ: Bowel symptoms | 0.26 (0.10 to 0.41) |
| SDT-IBDQ: Systemic symptoms | 0.18 (0.01 to 0.34) |
| SDT-IBDQ: Emotional function | 0.16 (-0.01 to 0.32) |
| SDT-IBDQ: Social function | 0.15 (-0.02 to 0.31) |
| SDT-WPAI: UC Work Productivity Loss Score | -0.14 (-0.36 to 0.09) |
| SDT-WPAI: UC Absenteeism Score | 0.03 (-0.17 to 0.22) |
| SDT-WPAI: UC Presenteeism Score | -0.17 (-0.38 to -0.06) |
| SDT-WPAI: UC Activity Impairment Score | -0.17 (-0.32 to -0.00) |
| SDT-Generalize Anxiety Disorder-7 Score | 0.03 (-0.14 to 0.19) |
| SDT- APU for BU | 0.07 (-0.09 to 0.23) |
| APU-IBDQ: IBDQ Total score | -0.290 (-0.436 to -0.126) |
| APU-IBDQ: Bowel symptoms | -0.240 (-0.392 to -0.073) |
| APU-IBDQ: Systemic symptoms | -0.160 (-0.319 to 0.010) |
| APU-IBDQ: Emotional function | -0.258 (-0.409 to -0.093) |
| APU-IBDQ: Social function | -0.321 (-0.464 to -0.160) |
| APU-WPAI: Work Productivity Loss Score | 0.040 (-0.194 to 0.269) |
| APU-WPAI: Absenteeism Score | -0.031 (-0.228 to 0.169) |
| APU-WPAI: Presenteeism Score | 0.030 (-0.204 to 0.259) |
| APU-WPAI: Activity Impairment Score | 0.153 (-0.010 to 0.308) |
| APU-WPAI: Generalize Anxiety Disorder-7 Score | 0.139 (-0.025 to 0.294) |
| UNRS: PGR-S | 0.672 (0.575 to 0.748) |
| UNRS: Mayo SF | 0.478 (0.348 to 0.589) |
| UNRS: Mayo RB | 0.368 (0.225 to 0.494) |
| UNRS: Abdominal Pain NRS | 0.667 (0.570 to 0.744) |
| UNRS: Fatigue NRS | 0.601 (0.491 to 0.691) |
| UNRS: Nocturnal Stool | 0.191 (0.036 to 0.335) |
| BUF: PGR-S | 0.502 (0.375 to 0.609) |
| BUF: Mayo SF | 0.477 (0.346 to 0.587) |
| BUF: Mayo RB | 0.351 (0.207 to 0.480) |
| BUF: Abdominal Pain NRS | 0.399 (0.258 to 0.521) |
| BUF: Fatigue NRS | 0.404 (0.264 to 0.525) |
| BUF: Nocturnal Stool | 0.579 (0.464 to 0.672) |
| SDT: PGR-S | -0.44 (-0.55 to -0.30) |
| SDT: Absolute SF | -0.23 (-0.37 to -0.08) |
| SDT: Mayo SF | -0.35 (-0.48 to -0.21) |
| SDT: Mayo RB | -0.22 (-0.37 to -0.07) |
| SDT: Abdominal Pain NRS | -0.39 (-0.52 to -0.25) |
| SDT: Fatigue NRS | -0.30 (-0.43 to -0.15) |
| SDT: Nocturnal Stool | -0.07 (-0.22 to 0.09) |
| APU: PGR-S | 0.047 (-0.114 to 0.206) |
| APU: Mayo SF | 0.177 (0.018 to 0.327) |
| APU: Mayo RB | 0.120 (-0.041 to 0.274) |
| APU: Abdominal Pain NRS | 0.168 (0.008 to 0.319) |
| APU: Fatigue NRS | 0.154 (-0.007 to 0.306) |
| APU: Nocturnal Stool | 0.115 (-0.047 to 0.270) |
Collected over Baseline Up to Week 12. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 300 mg Mirikizumab | 0/172 (0%) | 5/172 (2.9%) | 53/172 (30.8%) |
| Event | 300 mg Mirikizumab |
|---|---|
| Any eventBlood and lymphatic system disorders | 1/172 |
| AnaemiaBlood and lymphatic system disorders | 1/172 |
| Any eventGastrointestinal disorders | 1/172 |
| Colitis ulcerativeGastrointestinal disorders | 1/172 |
| Any eventInfections and infestations | 1/172 |
| Joint abscessInfections and infestations | 1/172 |
| Any eventRespiratory, thoracic and mediastinal disorders | 1/172 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/172 |
| Any eventVascular disorders | 1/172 |
| Deep vein thrombosisVascular disorders | 1/172 |
| Event | 300 mg Mirikizumab |
|---|---|
| Any eventGeneral disorders | 12/172 |
| Any eventInfections and infestations | 11/172 |
| Any eventGastrointestinal disorders | 10/172 |
| Upper respiratory tract infectionInfections and infestations | 7/172 |
| Any eventMetabolism and nutrition disorders | 6/172 |
| Any eventNervous system disorders | 6/172 |
| FatigueGeneral disorders | 5/172 |
| Any eventBlood and lymphatic system disorders | 4/172 |
| AnaemiaBlood and lymphatic system disorders | 4/172 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 4/172 |
All enrolled participants.
| Age, Continuous(years) | 300 mg Mirikizumab |
|---|---|
| Mean | 41.10 ± 14.352 |
| Sex: Female, Male(Participants) | 300 mg Mirikizumab |
|---|---|
| Female | 71 |
| Male | 101 |
| Ethnicity (NIH/OMB)(Participants) | 300 mg Mirikizumab |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 151 |
| Unknown or Not Reported | 15 |
| Race (NIH/OMB)(Participants) | 300 mg Mirikizumab |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 150 |
| More than one race | 1 |
| Unknown or Not Reported | 11 |
| Region of Enrollment(Participants) | 300 mg Mirikizumab |
|---|---|
| Hungary | 7 |
| United States | 33 |
| Czechia | 18 |
| Poland | 50 |
| Italy | 32 |
| United Kingdom | 6 |
| Slovakia | 10 |
| France | 16 |
Showing the first 100 of 120 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2023 to primary completion in Aug 2024, 14 months.
Results were first posted in Sep 2025, 1 year 1 month after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 14 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab